Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVGRNASDAQ:QNRXNYSE:RMED Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$3.85+4.1%$3.44$2.50▼$18.00$6.12M1.2645,830 shs12,431 shsQNRXQuoin Pharmaceuticals$0.63$1.38$0.60▼$12.00$2.33M1.81490,211 shs239,320 shsRMEDRa Medical Systems$0.73$0.52▼$11.14$3.19M-0.03197,480 shs77,500 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger+0.27%0.00%+30.28%+27.59%-56.22%QNRXQuoin Pharmaceuticals-5.30%-13.78%-25.72%-83.10%-89.65%RMEDRa Medical Systems0.00%0.00%0.00%0.00%-55.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvinger2.625 of 5 stars3.55.00.00.01.90.80.6QNRXQuoin Pharmaceuticals2.539 of 5 stars3.55.00.00.02.60.00.6RMEDRa Medical SystemsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger3.00Buy$5.0029.87% UpsideQNRXQuoin Pharmaceuticals3.00Buy$4.00534.92% UpsideRMEDRa Medical SystemsN/AN/AN/AN/ACurrent Analyst RatingsLatest QNRX, RMED, and AVGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024AVGRAvingerHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/15/2024QNRXQuoin PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.80N/AN/A($4.53) per share-0.85QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ARMEDRa Medical Systems$10K0.00N/AN/A$4.29 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$10.24N/A∞N/AN/A-105.09%-55.69%5/13/2024 (Estimated)RMEDRa Medical Systems-$26.86M-$92.36N/AN/AN/AN/A-496.57%-344.49%N/ALatest QNRX, RMED, and AVGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023AVGRAvinger$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 million3/13/2024Q4 2023QNRXQuoin Pharmaceuticals-$2.37-$2.08+$0.29-$2.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ARMEDRa Medical SystemsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A0.630.36QNRXQuoin PharmaceuticalsN/A3.153.15RMEDRa Medical SystemsN/A2.862.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%QNRXQuoin Pharmaceuticals8.63%RMEDRa Medical Systems11.00%Insider OwnershipCompanyInsider OwnershipAVGRAvinger11.40%QNRXQuoin Pharmaceuticals3.30%RMEDRa Medical Systems18.62%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger681.59 million1.41 millionNot OptionableQNRXQuoin Pharmaceuticals43.69 million3.56 millionNot OptionableRMEDRa Medical Systems145.37 million4.37 millionNot OptionableQNRX, RMED, and AVGR HeadlinesSourceHeadlineDietary Interventions Reduce CVD Risk in RA and SpAajmc.com - March 8 at 7:57 PMAlert1 Medical Alert System Review: What Experts Say (2024)forbes.com - February 20 at 9:27 PMRa Medical Systems Inc.thestreet.com - February 15 at 10:42 AMCatheter Precision Inc (VTAK)investing.com - February 11 at 11:09 PMVTAK Catheter Precision, Inc.seekingalpha.com - January 19 at 6:41 PMWhat Is The Life Expectancy Of Rheumatoid Arthritis? A Review By Doctorsmsn.com - January 7 at 11:58 PMCatheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Qfinance.yahoo.com - August 25 at 6:53 PMReminder: Ra Medical Systems Announces Name and Ticker Symbol Changesfinance.yahoo.com - August 17 at 9:15 AMRa Medical Systems, Inc.: Ra Medical Systems Announces Allowance of New Closure Device Patentfinanznachrichten.de - August 16 at 6:14 PMRa Medical Systems Announces Milestone Achievement for Electrophysiology Divisionfinance.yahoo.com - August 7 at 12:14 PMRa Medical Systems, Inc.: Ra Medical Systems Announces Proposed Name and Ticker Symbol Changesfinanznachrichten.de - August 2 at 8:13 AMRa Medical says demand is rising for its non-invasive electrophysiology mapping systemmassdevice.com - July 24 at 5:15 PMRa Medical Systems, Inc.: Ra Medical System's Electrophysiology Division Has Increased Demand for its Non-invasive Mapping Systemfinanznachrichten.de - July 24 at 12:14 PMRa Medical System’s Electrophysiology Division Has Increased Demand for its Non-invasive Mapping Systemfinance.yahoo.com - July 24 at 12:14 PMRa Medical Systems, Inc.: RMED's LockeT Device Utilized in Structural Heart Proceduresfinanznachrichten.de - July 6 at 10:17 AMRMED's LockeT Device Utilized in Structural Heart Proceduresfinance.yahoo.com - July 6 at 10:17 AMInvesting in Ra Medical Systems Inc (RMED): What You Must Knowknoxdaily.com - July 5 at 6:18 PMRa Medical Systems, Inc.: RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023finanznachrichten.de - June 28 at 9:07 AMRMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023finance.yahoo.com - June 28 at 9:07 AMRa Medical Systems, Inc.: Ra Medical's Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO Systemfinanznachrichten.de - June 12 at 4:10 PMRa Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO Systemfinance.yahoo.com - June 12 at 4:10 PMMedical Device Co. Completes Merger in Q1/23investorideas.com - June 9 at 9:35 PMRa Medical Systems reports Q1 resultsmsn.com - June 5 at 10:34 AMRa Medical Systems, Inc.: Ra Medical Systems Announces First Quarter Resultsfinanznachrichten.de - June 2 at 9:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentKeurig Dr Pepper Reaffirms Its Guidance, Time to Buy? April 1, 2024 6:15 AMView Keurig Dr Pepper Reaffirms Its Guidance, Time to Buy? When Will the Next Bull Market Be?April 15, 2024 9:25 AMView When Will the Next Bull Market Be?All Headlines Company DescriptionsAvingerNASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Quoin PharmaceuticalsNASDAQ:QNRXQuoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Ra Medical SystemsNYSE:RMEDRa Medical Systems, Inc develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. Ra Medical Systems, Inc is based in Fort Mill, South Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.